ACHN-490 is an aminoglycoside with activity against multidrug-resistant pathogens, including those resistant to currently used aminoglycosides. Two randomized, double-blind, placebo-controlled clinical studies investigated the pharmacokinetics (PK), safety, and tolerability of ACHN-490 injection in healthy subjects. Study 1 used a parallel-group design with escalating single (SD) and multiple doses (MD). Study 2 explored a longer duration of the highest dose tolerated in the first study. Subjects were randomly assigned to receive either ACHN-490 injection or a placebo administered by a 10-min intravenous infusion. Study 1 enrolled 39 subjects (30 active and 9 placebo) and consisted of a single dose of 1 mg/kg body weight followed by ascending SD and MD cohorts of 4, 7, 11, and 15 mg/kg for 10, 10, 5, and 3 days, respectively. Study 2 enrolled 8 subjects 
rotoxicity and ototoxicity are the primary adverse reactions associated with legacy AGs (e.g., gentamicin, amikacin). Oncedaily dosing of AGs is associated with lower rates of nephrotoxicity (16, 19) .
This report describes the pharmacokinetic (PK), safety, and tolerability results from two phase 1, randomized, doubleblind, placebo-controlled studies conducted with healthy human subjects to explore escalating once-daily single-dose (SD) and multiple-dose (MD) administration of ACHN-490 injection.
MATERIALS AND METHODS

Ethics.
The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Guidelines for Good Clinical Practice, and applicable regulatory requirements. Written informed consent was obtained before each subject entered the study and before initiation of protocol-specified procedures. The study protocols and the protocol amendments, as well as the informed consent form, the subject recruitment materials, and the investigator's brochure were reviewed and approved by institutional review boards. Study 1. The initial study (study 1) was a phase 1, randomized, double-blind, placebo-controlled, parallel-group, single-and multiple-dose escalation study to assess the PK characteristics, safety, and tolerability of ACHN-490 injection in healthy human (male and female) subjects ages 18 to 55 years. The female subjects of child-bearing potential included in these studies were required to be non-breast-feeding, have a negative serum pregnancy test, and use a highly effective method of contraception for at least 3 months before the first dose of ACHN-490, during the study, and through the last study day of the 6-month assessment. Subjects were confirmed to be in good health with physical examinations and assessment of blood and urine laboratory tests (including renal function), cochlear and vestibular function, and electrocardiogram (ECG) readings. Subjects were excluded from the study if there was any history of tinnitus or dizziness in the past 90 days, trauma to the outer or internal structure of the ear, and/or vestibular disorder. This study was designed to enroll 8 subjects into each of 4 cohorts (cohorts 1 [1a and 1b components], 2, 3, and 4), for a planned minimum of 32 subjects overall. Within each cohort, subjects were randomly assigned in a 3:1 ratio to receive either ACHN-490 injection (n ϭ 6 subjects) or placebo (normal saline; n ϭ 2 subjects) administered intravenously (IV) over a 10-min infusion. Each successive cohort was dosed higher than the level evaluated in the previous cohort (Table 1) . Subjects in each cohort, except cohort 1a, first received a single-dose infusion and then (at least 7 days later) received daily infusions for multiple days at the same dose level. Subjects from cohort 1a (1 mg/kg as a single dose) were rolled over into cohort 1b (4 mg/kg as a single dose followed by a multidose for 10 days). Different groups of subjects were enrolled into each of cohorts 2 (7 mg/kg as a single dose followed by multidose for 10 days), 3 (11 mg/kg as a single dose followed by multidose for 5 days), and 4 (15 mg/kg as a single dose followed by multidose for 3 days).
Study 2. This phase 1, randomized, double-blind, placebo-controlled, multipledose study was conducted to assess the PK, safety, and tolerability of ACHN-490 injection in healthy male and female subjects ages 18 to 65 years. Inclusion and exclusion criteria were similar to those in study 1. Eight subjects were randomly assigned in a 3:1 ratio to receive either ACHN-490 injection, 15 mg/kg, once daily (n ϭ 6 subjects) or placebo (normal saline; n ϭ 2 subjects) for 5 consecutive days. Subjects were restricted from exposure to loud noise during the study. The clinical procedures conducted in this study were similar to those conducted in study 1, except urine sampling for PK assessments, which was not collected in this study.
Pharmacokinetic evaluation. In study 1, blood samples were obtained for measurement of ACHN-490 plasma levels on the initial day and on selected days thereafter as follows: predose and 5, 10, 15, 20, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 , and 48 h after the start of infusion. For evaluation of trough concentrations in the multiple-dose regimens, samples were also taken predose, within 30 min prior to the ACHN-490 injection infusion, and on selected days between the first and last doses. Urine samples for measurement of ACHN-490 after the single dose and on the first and the last days of the multiple-dose regimen were obtained at the following time intervals: predose and 0 to 4, 4 to 8, 8 to 12, 12 to 16, 16 to 24, 24 to 36, and 36 to 48 h after the start of the ACHN-490 injection infusion.
In study 2, blood samples were obtained from all subjects on days 1 to 4 10 min prior to the start of the IV infusion (predose). On day 5, a full PK time course was obtained which included the following time points: predose and 10, 15, 20, 30, 45, and 60 min and 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 , and 24 h after the start of the IV infusion.
The liquid chromatography-tandem mass spectrometry (LC-MS/MS) analytical methods for plasma and urine measurements were developed and validated at Alturas Analytics, Inc. (Moscow, ID) (AV08-ACHN490-02). Briefly, a highperformance liquid chromatography (HPLC) column was used to separate ACHN-490 and its isotopically enriched [Mϩ6, (2 13 C, 4 3 H-ACHN-490)] internal standard from interfering compounds that may be present in the sample extract. The peak area of the product ion of ACHN-490 was measured against the peak area of the product ion of the internal standard. The interbatch percent coefficient of variation (CV) for all the quality control (QC) levels was within 9.5%, and the percent bias was within 3.0%. The intrabatch percent CV was within 5.6%, and the percent bias was within 7.7%. Plasma samples contained K 2 EDTA as the anticoagulant. Plasma and urine samples were analyzed for ACHN-490 levels using acid precipitation and quantitative LC-MS/MS. The plasma method has a calibration range of 0.01 to 5.0 g/ml, and the urine method has a calibration range of 0.50 to 50 g/ml. PK parameter estimates for ACHN-490 were calculated using standard noncompartmental methods of analysis (WinNonlin, version 5.2.1; Pharsight, Mountain View, CA), based upon the actual collection times. Descriptive statistics (n, mean, standard deviation) were used to summarize plasma and urine concentrations and pharmacokinetic parameters.
Safety monitoring. Monitoring procedures described in this section were conducted in both studies unless noted otherwise. Safety assessments included evaluation of adverse events (AEs), physical exam, hematology and serum chemistry panels, renal function, urinalysis, vital signs, cochlear function testing, and vestibular function testing. ECGs in triplicate also were performed prior to the first dose and postdosing on day 1 and day 5 in study 2. ECGs were taken immediately at the end of the 10-min infusion and then again 20 min after the completion of the infusion.
Renal function was assessed from blood urea nitrogen (BUN) and serum creatinine measurements, and creatinine clearance was calculated using the Cockcroft-Gault formula (6) . Creatinine clearance was measured from 24-hour urine collection at selected time points in study 1 only.
Cochlear function was assessed using pure tone audiometry (PTA), with bone conduction and otoacoustic emission (OAE). PTA was performed at baseline, at the end of treatment, and 3 and 6 months after treatment. OAE was performed at baseline, daily during treatment, and at the end of treatment. Vestibular function was evaluated at baseline, at the end of treatment, and 3 and 6 months after treatment by electronystagmography (ENG). Specifically, tests were conducted for unilateral weakness, directional preponderance, pendulum tracking, and fixation. For study 1, vestibular function also was evaluated by dynamic visual acuity (DVA) testing at baseline, daily during treatment, and at the end of treatment. For study 2, vestibular function also was evaluated by the modified Romberg test performed at baseline on day 1, prior to each dose during the consecutive dosing period, and 7 days after administration of the last dose.
Statistical methods. Descriptive statistics were used to summarize all baseline characteristics, treatment administration, and safety variables; statistical inference was secondary. Continuous variables were summarized using standard summary statistics (n, mean, standard deviation). Categorical or nominal variables were summarized by frequency and percentage. The denominator for percentage was the number of subjects with nonmissing data appropriate for summary purposes.
The last assessments/measurements before the first dose of randomized drug infusion on day 1 were used as the baseline reference for analyses unless stated otherwise. Nominal time points were used for analysis; actual assessment times were not used to reclassify the time point at which a measurement was taken. Version 9.1 (or higher) of the SAS statistical software package was used to generate the clinical summary tables, data listings, and analyses. No interim analyses were conducted.
The intent-to-treat (ITT) population included all subjects who were randomized, whether or not they were exposed to study drug. The safety population included all subjects who were randomized and received any amount of study drug. The PK population included subjects who received ACHN-490 injection and for whom at least 1 plasma PK variable was available. Individual plasma 
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a In study 1, those who received active drug versus placebo were distributed as follows: cohort 1a (6 active, 2 placebo), cohort 1b (6 active, 2 placebo), cohort 2 (8 active, 2 placebo), cohort 3 (8 active, 2 placebo), and cohort 4 (7 active, 2 placebo). In study 2, those who received active drug versus placebo were distributed as 6 active and 2 placebo. In study 1, 6 subjects completed treatment in cohort 1a (5 active, 1 placebo), 8 in cohort 1b (6 active, 2 placebo), 8 in cohort 2 (6 active, 2 placebo), 8 in cohort 3 (6 active, 2 placebo), 8 in cohort 4 (6 active, 2 placebo). In study 2, 7 subjects completed treatment (5 active, 2 placebo).
b Each dose was administered as an IV infusion over 10 min. SD, single dose; MD, multiple dose (MD administered once daily 
RESULTS
Demographics and patient disposition. The demographics of the ITT populations of subjects in the two studies are presented in Table 2 . In study 1, 39 subjects were enrolled (30 active, 9 placebo), 32 subjects completed the treatment period, and 7 subjects were withdrawn. Reasons for not completing the treatment period included withdrawal of consent (4 subjects: 1 subject in each of the 1-mg/kg and 11-mg/kg ACHN-490 injection groups and 2 subjects in the 7-mg/kg ACHN-490 injection group), subjects deemed unsuitable for further participation (2 subjects: 1 in the 11-mg/kg group for elevated serum creatinine and 1 in the 15-mg/kg group for positive drug screen). The involvement of one subject in the placebo group was discontinued for an increase in alanine aminotransferase. The safety population included 37 subjects in study 1. In study 2 (n ϭ 8 subjects), 5 subjects received ACHN-490 injection at 15 mg/kg for 5 days, 1 subject received ACHN-490 injection at 15 mg/kg for 3 days (subject withdrew for personal reasons after 3 doses), and 2 subjects received the placebo.
Pharmacokinetic results. Plasma and urine (study 1 only) PK parameters for ACHN-490 injection in healthy subjects following single or multiple 10-min intravenous infusions of ACHN-490 injection in both studies are presented in Tables 3  and 4 . In study 1, data for all 28 subjects who received ACHN-490 injection are included in the single-and multiple-dose PK analyses. The mean peak plasma ACHN-490 concentration was attained at or shortly after the end of the 10-min infusion (Fig. 1) . For the single doses, the mean Ϯ standard deviation C max ranged from 8 Ϯ 0.8 mg/liter in the 1-mg/kg group to 144 Ϯ 45 mg/liter in the 15-mg/kg group. After the infusion was terminated, the decline in ACHN-490 concentrations appeared to be multiphasic, with an initial rapid decline in plasma concentrations followed by a biphasic terminal phase and a slower decrease in drug concentrations beginning at about 16 or 24 h after dosing in most subjects. The elimination half-life estimates shown in Tables 3 and 4 represent the effective half-life and were generally measured in the intermediate terminal phase (though 12 h after dosing). Mean AUC 0-ϱ ranged from 15 Ϯ 1 h ⅐ mg/liter in the 1 mg/kg group to 246 Ϯ 39 h ⅐ mg/liter in the 15 mg/kg group. Study 1 results for AUC 0-ϱ versus dose (mg) and C max versus dose (mg) following the initial once-daily 10-min intravenous infusion of ACHN-490 injection in healthy subjects are shown in Fig. 2A and B, respectively. ACHN-490 plasma PK was linear and dose proportional.
The mean plasma PK parameters after multiple doses of 4, 7, and 11 mg/kg were generally similar to their single-dose PK parameters shown in Table 3 . The mean plasma PK parameters after multiple 15-mg/kg doses also were generally similar to the single-dose parameters (Tables 4 and 3, respectively) . For the multiple doses, the mean Ϯ standard deviation C max ranged from 31 Ϯ 2.5 mg/liter in the 4-mg/kg group to 117 Ϯ 28 mg/liter in the 15-mg/kg group. Mean AUC 0-24 ranged from 54 Ϯ 5 h ⅐ mg/liter in the 4-mg/kg group to 235 Ϯ 44 h ⅐ mg/ liter in the 15-mg/kg group. The mean elimination half-lives were similar across all dose groups, SD and MD in both studies, ranging from 3 to 4 h. The mean ACHN-490 clearances and steady-state volumes of distribution were also similar across all dose groups, with no evidence of dose dependence seen. On the last day of dosing in both studies, the 24-hour plasma concentration was low, averaging between 0.09 Ϯ 0.02 mg/liter in the 4-mg/kg dose group to 0.4 Ϯ 0.1 mg/liter in the 15-mg/kg dose group. Steady-state trough levels appear to have been attained after the second dose of ACHN-490 injection.
In study 1, mean ACHN-490 urine concentrations after a single 10-min intravenous infusion of ACHN-490 injection were highest in the first two postdose collection intervals (0 to 4 and 4 to 8 h), with mean urine concentrations for the 0-to-4-h interval ranging from 53.4 Ϯ 18.4 mg/liter after a 1-mg/kg dose to 805 Ϯ 236 mg/liter after a 15-mg/kg dose (Fig. 3) . Urinary Multidose, day 1 (n ϭ 6 subjects)
Single dose (n ϭ 5 subjects) Multidose, day 1 (n ϭ 6 subjects) Single dose (n ϭ 6 subjects) Multidose, day 1 (n ϭ 6 subjects) Single dose (n ϭ 6 subjects) Multidose, day 1 (n ϭ 6 subjects) b C max , maximum plasma drug concentration; AUC 0-24 , area under the concentration time curve from time zero to 24 h; C min , minimum plasma drug concentration for the dosing interval; t 1 ⁄2, apparent elimination half-life; V ss , w, steady-state volume of distribution, adjusted for body weight; CL, w, systemic clearance, adjusted for body weight; Ae (%), fraction of drug excreted in the urine over the dosing interval; CLr, w, renal clearance, adjusted for body weight.
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on July 1, 2017 by guest http://aac.asm.org/ excretion levels of ACHN-490 were high and similar among dose groups, with mean values ranging from 85% of the administered dose in the 11-mg/kg group to 92% of the administered dose in the 7-mg/kg group. No dose-related trends were apparent for renal clearance, which averaged 0.76 ml/min/kg in the 15-mg/kg dose group to 1.27 ml/min/kg in the 7-mg/kg dose group. Safety and tolerability results. No subjects' receipt of ACHN-490 injection was discontinued because of a treatmentemergent AE (TEAE). For study 1, the most frequently observed TEAEs were headache, dizziness (including lightheaded and lightheadedness), somnolence, and blurred vision (Table 5) . Headache, dizziness, and blurred vision occurred in both ACHN-490 injection-and placebo-treated subjects. Somnolence occurred only in ACHN-490 injection subjects. All TEAEs were mild or moderate in severity and resolved without sequelae. No severe or potentially life-threatening TEAEs occurred. One subject in the 11-mg/kg group was discontinued for a serum creatinine value of 1.5 mg/dl after a single dose of drug, rising from 1.3 mg/dl at screening. Although the rise was attributed to laboratory testing variability, the subject at that point no longer satisfied inclusion criteria for the study. One serious AE (schizoaffective disorder) occurred in a subject who had withheld a history of the disorder during the screening process and discontinued his medication prior to enrollment and treatment. This event was not considered related to study drug.
In study 2, no subject had a serious TEAE, a severe or life-threatening TEAE, or a TEAE leading to study discontinuation. The most common TEAEs were dizziness, oral hypoaesthesia, somnolence, and blurred vision (Table 5) . ECG findings revealed no occasions in which QTcF (or QTcB) values were Ͼ450 msec and no QTcF (or QTcB) increases from baseline were Ն30 msec. One subject who received ACHN-490 injection had a TEAE of nonspecific T-wave changes; however, this event was considered unrelated to study drug.
In both studies, no clinically relevant differences in laboratory values, ECG results, or physician examination results were observed between ACHN-490 injection and placebo.
Vestibular and cochlear function. In both studies, vestibular function (ENG, DVA, or modified Romberg test) and cochlear function (pure tone audiometry with bone conduction as well as OAE signal-to-noise ratio) testing revealed no abnormal results for up to 6 months after dosing among subjects given ACHN-490 injection. In study 1, two reports of tinnitus occurred, 1 in the 11-mg/kg group after a single dose and 1 in the 15-mg/kg group before administration of the first dose during the multiple-dose period. Both of these events were mild, deemed not drug related, and resolved on the same day. Both subjects had normal vestibular and cochlear function testing.
Renal function. In both studies, analyses of BUN and serum creatinine, as well as calculated creatinine clearance, revealed no overall effects on renal function with ACHN-490 injection. BUN and serum creatinine values remained within the normal limits throughout the treatment period for most subjects in both ACHN-490 injection and placebo groups; however, three subjects (two ACHN-490 injection subjects and one placebo subject) had a mild, transient elevation of serum creatinine in study 1. In addition, two other subjects given ACHN-490 injection in study 1 had a transient decrease in calculated creatinine clearance slightly below the lower limit of normal. All of these levels returned to the normal range during treatment. In study 1, measured creatinine clearances based on 24-hour urine data were similar between ACHN 490 injection and placebo groups, and measured creatinine clearances remained within normal limits throughout the treatment period. Overall, no evidence of treatment-related effects on renal function or glomerular filtration rate (GFR) was observed.
DISCUSSION
The aminoglycoside agents gentamicin and tobramycin are frequently dosed at 5 to 7 mg/kg once daily. This dosing schedule formed the basis of dose selection for ACHN-490 injection in the current study. ACHN-490 injection given at doses of 4 and 7 mg/kg for 10 days bracketed clinically relevant regimens for the older agents. ACHN-490 injection doses were then increased while shortening the durations to maintain similar cumulative exposures given over shorter durations. The dose escalation study (study 1) showed that ACHN-490 exposure, as measured by AUC and C max , increased in a linear and proportional fashion with increasing dose. Across all dose groups, the single-dose and the multidose PK look similar, with no evidence of accumulation after once-daily dosing, even at the highest dose (15 mg/kg), which is consistent with the apparent (beta-phase) elimination half-life of 2 to 3 h. Population PK modeling showed that the PK data can be described by a 3-compartment pharmacokinetic model that has a very long terminal elimination phase (21) . No evidence of dose-dependent clearance is apparent within the ACHN-490 injection doses tested. High plasma ACHN-490 peak concentrations and low trough concentrations were observed after 10-min oncedaily IV infusions. The peak-to-trough ratio was high and consistent with a once-daily dosing interval, with a fluctuation index value averaging Ͼ1,000%. In study 1, the average C max and minimum plasma drug concentration (C min ) for the 15-mg/kg single once-daily dose were 144 and 0.2 g/ml, respectively. Initial, 0-to-4-h-collection-interval urine concentrations of ACHN-490 were high, averaging 805 mg/liter after a 15-mg/kg dose. The PK profile of ACHN-490 injection at 15 mg/kg administered once daily for 5 days in study 2 was predictable, with high peak and low trough concentrations.
High plasma AUC 0-ϱ values, relative to likely pathogenic MICs, of ACHN-490 injection were achieved in the 15-mg/kgdose group after ACHN-490 injection administration. This high plasma AUC value suggests a favorable AUC/MIC ratio, which for aminoglycosides is the primary PK/PD driver for efficacy (2, 7) . ACHN-490 has demonstrated potent in vivo efficacy against a variety of drug-resistant and -susceptible pathogens in two different murine models, the neutropenic thigh and septicemia (18) . The mean Ϯ standard deviation ACHN-490 plasma protein binding levels are low and similar for both human and mouse, 16% (Ϯ5) and 14% (Ϯ8), respectively. From these data, the expected AUC/MIC targets of 80 and 160 for Escherichia coli (MIC Յ 1) and Klebsiella pneumoniae (MIC Յ 0.5), respectively, should be achievable in humans at the 7-mg/kg dose level. For aminoglycosides, AUC is an important predictive PK parameter of efficacy (22) ; however, a high C max may provide an independent effect beyond that contributed by AUC alone (4, 5, 15, 20) , is correlated with better tissue penetration (11) , and is important in preventing adaptive resistance (5) . A higher C max for a given AUC can be achieved by delivering the total daily dose in a single administration (i.e., once-daily dosing). The beneficial effect of high Nasal congestion/respiratory 1 (9) 1 (17) 1 (14) 3 (7) Phlebitis/vascular 2 (18) 1 (17) 3 (7) Nasopharyngitis/infections 1 (9) 1 (14) 1 (14) 3 ( C max values on efficacy justifies evaluation of higher doses of these compounds, up to 15 mg/kg in the present study. ACHN-490 injection was well tolerated in both studies. In study 1, all TEAEs were mild or moderate in severity, and the overall frequencies of TEAEs were similar between ACHN-490 injection and placebo groups. AEs were mild to moderate, transient, and rapidly resolved. In study 1, no evidence of nephrotoxicity or ototoxicity was observed in healthy subjects. All subjects had normal vestibular function by ENG and DVA. Tinnitus was reported in 1 subject each receiving 11 mg/kg and 15 mg/kg ACHN-490 injection, respectively; both had normal cochlear and vestibular function. One case of tinnitus occurred prior to the first dose in the multiple-dose period, and the second case occurred the day of a single-dose injection. Neither event was judged by investigators as drug related. Further investigation of tinnitus is recommended in future studies.
In study 2, ACHN-490 injection also was well tolerated using a once-daily regimen of 15 mg/kg for 5 days in normal volunteers. The AE profile in study 2 was similar to that observed in study 1, with no evidence of nephrotoxicity or ototoxicity. Additionally, no changes to QT intervals were noted. Nonspecific T-wave changes reported in one subject could have been caused by hyperventilation (10) , but these changes were deemed unrelated to treatment with ACHN-490 injection in our studies.
Although the numbers of subjects participating in these two studies were small, the results indicate that ACHN-490 injection given in single and multiple doses of up to 15 mg/kg, including the 5-day dosing regimen in study 2, were generally well tolerated. No major safety concerns were identified that would preclude further clinical development of ACHN-490 injection.
In conclusion, ACHN-490 injection is an aminoglycoside with activity against MDR Gram-negative pathogens and MRSA and is a promising agent for the treatment of serious infections, including those caused by multiple drug-resistant pathogens. Our results showed a linear and dose-proportional PK profile after single and multiple doses of the ACHN-490 injection up to a 15-fold dose range and no evidence of treatment-related side effects or effects on renal, cochlear, or vestibular functions that would preclude further clinical development.
